Results 91 to 100 of about 2,272 (175)
Infection and Drug Resistance, 2022 Qian Zhou,1,2,* Wenqi Xu,1,2,* Xiaoyu Zhu,1,2 Jin Zhang,1,2 Yan Zhang,1,2 Yan Han,1,2 Kai Chen,1,2 Yueping Yin1,2 1Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, People’s Republic of China;
Zhou Q +7 more
doaj
Infection and Drug Resistance, 2023 Xuehan Zou,1,* Shaojun Jin,2,* Lingxia Chen,1,* Jie Li,1 Xiaofan Zhang,3 Hua Zhou,4 Xi Li,3 Haijun Huang1 1Center for General Practice Medicine, Department of Infectious Diseases, Zhejiang Provincial People’s Hospital, Affiliated People’s ...
Zou X +7 more
doaj
BMC MicrobiologyBackground Acinetobacter baumannii is an obligately aerobic, non-motile, non-fermenting, gram-negative, opportunistic pathogen. The fact that this pathogen, which is the leading cause of nosocomial infections, is naturally resistant to many antibiotics ...
Merve Ataman, Berna Özbek Çelik
doaj +1 more source
, 2017 Importance: Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class with in vitro activity against clinically important gram-negative, gram-positive aerobic, and facultative bacteria including most of those resistant ...
Lee, Patrick, MD
core +1 more source
Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline
ACS Infectious DiseasesPseudomonas aeruginosa is a leading bacterial pathogen that causes persistent infections. One major reason that antibiotics fail to clear such infections is the presence of a dormant subpopulation called persister cells. To eradicate persister cells, it is important to change drug development from traditional strategies that focus on growth inhibition ...
Sweta Roy +5 more
openaire +2 more sources
Clinical Efficacy of Eravacycline in the Treatment of Pneumonia: A Multicenter Real World Study
Xiehe Yixue ZazhiObjectiveTo evaluate the efficacy and safety of eravacycline in the treatment of pulmonary infections based on real-world data.MethodsThis multicenter retrospective cohort study enrolled patients with pulmonary infections who received eravacycline ...
WANG Di +7 more
doaj +1 more source
In vitro efficacy of eravacycline on carbapenem-resistant
, 2022 Enterobakterije otporne na karbapeneme (eng. Carbapenem-Resistant Enterobacteriaceae, CRE) su razvile sposobnost stvaranja beta-laktamaza KPC, VIM, NDM i OXA-48 zbog sve veće uporabe karbapenema u kliničkoj praksi te predstavljaju veliku opasnost za ...
Jurić, Ivana
core
, 2018 The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens.
Trudy H. Grossman +5 more
core +1 more source
In vitro activity of omadacycline and eravacycline against Nocardia brasiliensis isolates
Frontiers in Tropical DiseasesActinomycetoma is a chronic, debilitating, neglected tropical disease primarily caused by Nocardia brasiliensis in Mexico and Central America. Current therapeutic standards involving high-dose trimethoprim–sulfamethoxazole are often complicated by ...
Hassiel Aurelio Ramírez-Marín +2 more
doaj +1 more source